Live Evaluations

The PA and NPs Role in Managing Atopic Dermatitis With Biologics in Clinical Practice: FCPANP23 Satellite Symposium


CME Satellite Symposium: The PA and NPs Role in Managing Atopic Dermatitis With Biologics in Clinical Practice

This activity is supported by educational grants from LEO Pharma, Lilly, and Sanofi and Regeneron Pharmaceuticals, Inc.

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Overview the role of biologics for the management of moderate-to-severe atopic dermatitis

  • Identify patients who would benefit from biologics for the management of moderate-to-severe atopic dermatitis

  • Discuss how PAs and NPs can work in a multidisciplinary team to manage patients with moderate-to-severe AD on biologics

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Christopher Bunick, MD, PhD

Associate Professor of Dermatology
Yale University School of Medicine
New Haven, CT

Lauren Miller, MPAS, PA-C

Southern Skies Dermatology & Surgery
Oxford, AL

Gil Yosopovitch

Professor, Department of Dermatology and Cutaneous Surgery

Director, Miami Itch Center 

University of Miami Miller School of Medicine

Miami, FL

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers


In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

Christopher G. Bunick, MD, PhD

Grant/Research Support: Almirall

Lauren Miller, MPAS, PA-C

Consultant: Abbvie, BMS, Dermavant, EPI, Lilly, Mayne, Novartis, Sanofi Genzyme Regeneron 

Speaker's Burea: Abbvie, BMS, Dermavant, Lilly, Sanofi Genzye Regeneron

Gil Yosopovitch

Grant/Research Support: Eli Lilly, Escient, Galderma, Maruho, Pfizer, Sanofi Regeneron

Consultant: Abbvie, Arcutis,. Escient Health, Eli Lilly, Galderma, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc., Sanofi, Vifor 

Speaker's Bureau: Maruho

Intellectual Property Rights: APAP cream

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.


The leading platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2023 dermsquared | All Rights Reserved